DWTX: Interim Readout for Halneuron Phase 2b Trial in CINP in 4Q25
On November 6, 2025, Dogwood Therapeutics, Inc. announced financial results for the third quarter of 2025 and provided a business update. The...
152 Views
DWTX: Licenses SP16 for Treatment of Cancer Related Pain
On September 29, 2025, Dogwood Therapeutics, Inc. announced it had secured a worldwide, royalty free license to develop SP16 for the treatment of...
382 Views
DWTX: Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron Trial Interim Read Out in 4Q25
On August 13, 2025, Dogwood Therapeutics, Inc. announced financial results for the second quarter of 2025 and provided a business...
151 Views
DWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway
On May 8, 2025, Dogwood Therapeutics, Inc. announced financial results for the first quarter of 2025 and provided a business update. The company...
182 Views
DWTX: Interim Data for Phase 2b Trial in 4Q25
On March 31, 2025, Dogwood Therapeutics, Inc. announced financial results for 2024 and provided a business update. The company recently dosed the...
407 Views